CTOR

#4112
Citius Oncology, Inc. - Common Stock
0.7 8 USD
-0.01%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
0.78
0.78
Intervallo Annuale
0.49
1.22
Variazione giornaliera
-1.27%
Variazione Mensile
+30.00%
Variazione di 6 mesi
-28.44%
Variazione Annuale
-32.76%
Chiusura Precedente
0.7 9
Open
0.7 8
Minimo
0.7 8
Massimo
0.7 8
Volume
1
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
CITIUS ONCOLOGY, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
CITIUS ONCOLOGY, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
CITIUS ONCOLOGY, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
CITIUS ONCOLOGY, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
CITIUS ONCOLOGY, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
CITIUS ONCOLOGY, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
CITIUS ONCOLOGY, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
CITIUS ONCOLOGY, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
CITIUS ONCOLOGY, INC. current report, Q2 FY2026
8-K
Quarterly report, Q2 FY2026
CITIUS ONCOLOGY, INC. quarterly report, Q2 FY2026
10-Q

CITIUS ONCOLOGY, INC. current report, Q3 FY2026

Full document

CITIUS ONCOLOGY, INC. - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Citius Oncology, Inc. (Nasdaq: CTOR) on August 7, 2026. The Company is incorporated in Delaware and is classified as an emerging growth company. The report details a corporate governance event regarding the expansion of the Board of Directors.

Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel appointment and does not contain financial statements or performance data.

Material Changes

The primary material change reported is the expansion of the Board of Directors from its previous size to nine individuals. The Board appointed Jonathan Peri, Ph.D., J.D., as a Class I director, effective August 10, 2026. Dr. Peri's term will last until the 2028 annual meeting of stockholders or until a successor is elected. The Board has determined that Dr. Peri is an independent director, and the Board remains majority independent following this appointment.

Guidance, Outlook, and Management Commentary

Management commentary is limited to the rationale for the appointment. The Corporate Governance and Nominating Committee selected Dr. Peri following a broad process, citing his strength of character, mature judgment, and relevant technical skills. Dr. Peri brings experience as the President of Manor College and as an elected Commissioner of the Middle States Commission on Higher Education. No financial guidance, outlook, risks, or contingencies are disclosed in this filing.

Key Facts for Investor Verification

  • Board Composition: Verify the total number of directors is now nine and that the Board remains majority independent.
  • Director Independence: Confirm Dr. Peri's independence status under SEC and Nasdaq rules as stated by the Board.
  • Compensation Review: Note that the Company's compensation program for independent directors is currently undergoing review by the Board.
  • Effective Date: Confirm Dr. Peri's appointment is effective August 10, 2026.
  • Related Transactions: The filing states there are no undisclosed transactions in which Dr. Peri had a material interest.